WallStSmart

CryoCell International Inc (CCEL)vsEncompass Health Corp (EHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Encompass Health Corp generates 19837% more annual revenue ($6.21B vs $31.13M). EHC leads profitability with a 10.0% profit margin vs -7.9%. EHC appears more attractively valued with a PEG of 0.41. EHC earns a higher WallStSmart Score of 71/100 (B).

CCEL

Buy

50

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 7.0Quality: 5.5
Piotroski: 6/9Altman Z: -0.53

EHC

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 7.5Value: 6.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.12
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCELUndervalued (+33.9%)

Margin of Safety

+33.9%

Fair Value

$5.05

Current Price

$3.99

$1.06 discount

UndervaluedFair: $5.05Overvalued
EHCSignificantly Overvalued (-51.9%)

Margin of Safety

-51.9%

Fair Value

$74.69

Current Price

$122.21

$47.52 premium

UndervaluedFair: $74.69Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL3 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

EPS GrowthGrowth
72.1%10/10

Earnings expanding 72.1% YoY

Debt/EquityHealth
-0.5010/10

Conservative balance sheet, low leverage

EHC2 strengths · Avg: 9.5/10
PEG RatioValuation
0.4110/10

Growing faster than its price suggests

Return on EquityProfitability
23.9%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

CCEL4 concerns · Avg: 2.0/10
Market CapQuality
$35.48M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Altman Z-ScoreHealth
-0.532/10

Distress zone — elevated risk

Profit MarginProfitability
-7.9%1/10

Currently unprofitable

EHC1 concerns · Avg: 3.0/10
Debt/EquityHealth
1.093/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : EHC

The strongest argument for EHC centers on PEG Ratio, Return on Equity. PEG of 0.41 suggests the stock is reasonably priced for its growth.

Bear Case : CCEL

The primary concerns for CCEL are Market Cap, Revenue Growth, Altman Z-Score.

Bear Case : EHC

The primary concerns for EHC are Debt/Equity.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while EHC is a value play — different risk/reward profiles.

EHC carries more volatility with a beta of 0.61 — expect wider price swings.

EHC is growing revenue faster at 9.6% — sustainability is the question.

EHC generates stronger free cash flow (62M), providing more financial flexibility.

Bottom Line

EHC scores higher overall (71/100 vs 50/100). CCEL offers better value entry with a 33.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

Encompass Health Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Encompass Health Corporation offers in-home and post-acute health care services in the United States. The company is headquartered in Birmingham, Alabama.

Want to dig deeper into these stocks?